IL312709A - Inhibitors of 1,3,4,7-tetrahydro-2H-pyrrolo [3',2':5,6]pyrido[2,3-B] [1,4]oxazepine BC1-2 - Google Patents

Inhibitors of 1,3,4,7-tetrahydro-2H-pyrrolo [3',2':5,6]pyrido[2,3-B] [1,4]oxazepine BC1-2

Info

Publication number
IL312709A
IL312709A IL312709A IL31270924A IL312709A IL 312709 A IL312709 A IL 312709A IL 312709 A IL312709 A IL 312709A IL 31270924 A IL31270924 A IL 31270924A IL 312709 A IL312709 A IL 312709A
Authority
IL
Israel
Prior art keywords
oxazepine
pyrido
pyrrolo
tetrahydro
inhibitors
Prior art date
Application number
IL312709A
Other languages
English (en)
Hebrew (he)
Inventor
Vikram Bhat
Patrick Brady
Yujia Dai
George A Doherty
Jianchun Gong
Andrew S Judd
Andrew J Souers
Yiyun Yu
Original Assignee
Abbvie Inc
Vikram Bhat
Patrick Brady
Yujia Dai
George A Doherty
Jianchun Gong
Andrew S Judd
Andrew J Souers
Yiyun Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Vikram Bhat, Patrick Brady, Yujia Dai, George A Doherty, Jianchun Gong, Andrew S Judd, Andrew J Souers, Yiyun Yu filed Critical Abbvie Inc
Publication of IL312709A publication Critical patent/IL312709A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL312709A 2022-01-21 2023-01-20 Inhibitors of 1,3,4,7-tetrahydro-2H-pyrrolo [3',2':5,6]pyrido[2,3-B] [1,4]oxazepine BC1-2 IL312709A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263267018P 2022-01-21 2022-01-21
PCT/US2023/060944 WO2023141536A1 (en) 2022-01-21 2023-01-20 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors

Publications (1)

Publication Number Publication Date
IL312709A true IL312709A (en) 2024-07-01

Family

ID=85382827

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312709A IL312709A (en) 2022-01-21 2023-01-20 Inhibitors of 1,3,4,7-tetrahydro-2H-pyrrolo [3',2':5,6]pyrido[2,3-B] [1,4]oxazepine BC1-2

Country Status (13)

Country Link
US (3) US11964990B2 (cg-RX-API-DMAC7.html)
EP (1) EP4466273A1 (cg-RX-API-DMAC7.html)
JP (2) JP7714811B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240136972A (cg-RX-API-DMAC7.html)
CN (1) CN119053610A (cg-RX-API-DMAC7.html)
AR (1) AR128310A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023210279A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242074A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009334A2 (cg-RX-API-DMAC7.html)
IL (1) IL312709A (cg-RX-API-DMAC7.html)
MX (1) MX2024008840A (cg-RX-API-DMAC7.html)
TW (1) TW202340210A (cg-RX-API-DMAC7.html)
WO (1) WO2023141536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑
CN117820134A (zh) * 2024-01-10 2024-04-05 山东盛安贝新材料有限公司南京分公司 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002032A (es) 2017-08-23 2020-09-17 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de bcl-2.
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
MX2022010410A (es) 2020-02-24 2022-12-07 Guangzhou Lupeng Pharmaceutical Company Ltd Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑

Also Published As

Publication number Publication date
AU2023210279A1 (en) 2024-05-23
JP2025504382A (ja) 2025-02-12
CA3242074A1 (en) 2023-07-27
AR128310A1 (es) 2024-04-17
CO2024009334A2 (es) 2024-07-18
TW202340210A (zh) 2023-10-16
US20230234971A1 (en) 2023-07-27
KR20240136972A (ko) 2024-09-19
US20250066388A1 (en) 2025-02-27
MX2024008840A (es) 2024-07-25
EP4466273A1 (en) 2024-11-27
JP7714811B2 (ja) 2025-07-29
WO2023141536A1 (en) 2023-07-27
US11964990B2 (en) 2024-04-23
US20260028356A1 (en) 2026-01-29
CN119053610A (zh) 2024-11-29
JP2025160251A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
IL284228A (en) imidazo[1,2-b]pyridazine il-17a inhibitors
IL289186A (en) Compounds of 4,4a,5,7,8,8a - hexapyrido[4,3-b][1,4]oxazin-3-one as inhibitors of magl
IL185510A0 (en) Fused thieno [2,3-b] pyridine and thiazolo [5,4-b] pyridine compounds for inhibiting ksp kinesin activity
NZ600161A (en) Novel tricyclic compounds
IL162461A0 (en) Polymorphs of clopidogrel hydrogensulfate
IL175813A0 (en) PYRIDO [2,3-d] PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS
ZA200504238B (en) Thieno[3,2-b]pyridine-6-carbonitriles and thienoo[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
TW200738672A (en) Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
IL151646A0 (en) Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction
IL315842A (en) Pyrido-[4,3-D]pyridazine amine derivatives are useful as NLRP3 derivatives
ZA202210773B (en) Pyrido[2,3-b] [1,4] oxazines or tetrahydropyrido[2,3-b][1,4] oxazepines as iap antagonists
HK40120239A (en) 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors
MX2024008840A (es) Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina.
WO2007010138A3 (fr) Derives de ν-(arylalkyl)-1h-pyrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
UA80881C2 (en) New polymorphs of olanzapine hydrochloride
SI1879893T1 (sl) Postopek za izdelavo substituiranih H imidazo c kinolin aminskih spojin in intermediatov zanje
PL4153599T3 (pl) Sposób wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4-b]pirydynokarboksylanu alkilu
ZA200704709B (en) A process for the preparation of substantially pure 4-mino-1-isobutyl-1H-imidazo[4,5-c]-quinoline (imiquimod)
HK40088610A (en) Pyrido[2,3-b] [1,4] oxazines or tetrahydropyrido[2,3-b][1,4] oxazepines as iap antagonists
IL175957A0 (en) Novel crystalline forms of 2,3 dimethyl-8-(2,6-dimethylbenzylamino)-n-hydroxyethyl-imidazo[1,2-a] pyridine-6-carboxamide mesylate salt
ZA202406459B (en) Pyrido[1,2-a]pyrimidin-4-one derivatives
HK40130916A (en) 3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors
CA3271103A1 (en) 3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors
ZA200707302B (en) Fused thieno [2,3-B] pyridine and thiazolo [5,4-B] pyridine compounds for inhibiting KSP kinesin activity
PL363207A1 (en) New derivative of pyrido [2,3-b] [1,4] diazepine and method for its production